⚠ Firefly and Sail Arrive as ChargesModerate threat

Johnson & Johnson (JNJ) — threat to the moat

Two small science deals in July 2026 took $0.64 off this year's adjusted earnings per share and $1.36 off next year's.

Early-stage purchases show up first as a cost. On 29 July 2026 J&J completed the acquisition of Firefly Bio for $1 billion in cash, accounted for as an asset acquisition that produces an in-process research and development charge of approximately $1 billion in the third quarter of 20261. The same day it announced agreements with Sail Biomedicines, including total initial payments of $785 million and an option to acquire Sail for $2.58 billion2.

Adjusted EPS dilution from the July 2026 deals ($)0.46Firefly 20260.18Sail 20260.08Firefly 20271.28Sail 2027J&J Form 8-K, 29 July 2026
The larger cost lands next year.

The effect on the earnings J&J reports to investors is immediate. The two transactions reduce 2026 adjusted EPS by approximately $0.64, and J&J cut its guidance midpoint from $11.68 to $11.043. For 2027 the expected reduction is approximately $1.36, most of it attributable to Sail if the option is exercised4.

Because J&J counts these research charges inside adjusted earnings, the deals move the number investors watch most. That is conservative accounting, and it makes the cost of the strategy visible.

The guidance change is also a change in margin. J&J now expects its adjusted pre-tax operating margin to decrease by about 75 basis points against 2025, where it had expected an increase of about 75 basis points5. A swing of 150 basis points from two deals shows how much early-stage science J&J is willing to absorb into the earnings it reports to investors.

The pattern is familiar from 2024, when J&J recorded $1.25 billion to secure the global rights to the NM26 bispecific antibody through the Yellow Jersey acquisition6 and research and development expense rose 14.2%7. Early-stage deals make J&J's research spending lumpy, and its adjusted earnings with it.

Adjusted EPS growth in 2027, after the $1.36 hit, is the proof. If the base business grows enough to show growth anyway, the purchases are affordable; if not, they are being paid for with a year of earnings.

References
  1. ReportedOn 29 July 2026 J&J completed the acquisition of Firefly Bio for $1 billion in cash, accounted for as an asset acquisition that produces an in-process research and development charge of approximately $1 billion in the third quarter of 2026.
    Johnson & Johnson announcement completing the acquisition of Firefly Bio, Form 8-K exhibit 99.1. — July 2026 · publ. 29 July 2026 · source ↗
  2. ReportedThe same day it announced agreements with Sail Biomedicines, including total initial payments of $785 million and an option to acquire Sail for $2.58 billion.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  3. ReportedThe two transactions reduce 2026 adjusted EPS by approximately $0.64, and J&J cut its guidance midpoint from $11.68 to $11.04.
    Johnson & Johnson Form 8-K of 29 July 2026 - updated 2026 guidance after the Firefly and Sail transactions, and the 2027 dilution. — July 2026 · publ. 29 July 2026 · source ↗
  4. ReportedFor 2027 the expected reduction is approximately $1.36, most of it attributable to Sail if the option is exercised.
    Johnson & Johnson Form 8-K of 29 July 2026 - updated 2026 guidance after the Firefly and Sail transactions, and the 2027 dilution. — July 2026 · publ. 29 July 2026 · source ↗
  5. ReportedJ&J now expects its adjusted pre-tax operating margin to decrease by about 75 basis points against 2025, where it had expected an increase of about 75 basis points.
    Johnson & Johnson Form 8-K of 29 July 2026 - updated 2026 guidance after the Firefly and Sail transactions, and the 2027 dilution. — July 2026 · publ. 29 July 2026 · source ↗
  6. ReportedThe pattern is familiar from 2024, when J&J recorded $1.25 billion to secure the global rights to the NM26 bispecific antibody through the Yellow Jersey acquisition and research and development expense rose 14.2%.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: rebate accrual tables, research and development, cost of products sold, debt and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  7. ReportedThe pattern is familiar from 2024, when J&J recorded $1.25 billion to secure the global rights to the NM26 bispecific antibody through the Yellow Jersey acquisition and research and development expense rose 14.2%.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: rebate accrual tables, research and development, cost of products sold, debt and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
Sources
Generated September 24, 2026